1 Retrospective Analysis of Blood Biomarkers of Neurological Injury in Human Cases of

2 Viral Infection and Bacterial Sepsis

3 Maggie L. Bartlett^{1,2}, Heather Goux^{1,2}, Linwood Johnson^{1,2}, Kevin L. Schully³, Melissa

4 Gregory⁴, Joost Brandsma⁴, Josh G. Chenoweth⁴, Danielle V. Clark⁴, Luis Felipe Rivera^{7,8},

5 Carlos Lezcano-Coba^{7,8}, Amy Y. Vittor⁵, Ronald Hayes⁶, Josefrancisco Galué^{7,8}, Jean-Paul

6 Carrera^{7,8,9}, Darci R. Smith¹

7

¹Naval Medical Research Command, Biological Defense Research Directorate, Microbiology 8 and Immunology Department; Ft. Detrick, MD, ²Parsons Corporation, Health and Biosciences; 9 Centreville, VA, ³Naval Medical Research Command, Biological Defense Research Directorate, 10 ACESO Department; Ft. Detrick, MD, ⁴The Austere environments Consortium for Enhanced 11 Sepsis Outcomes, The Henry M. Jackson Foundation for the Advancement of Military Medicine 12 Inc., Bethesda, MD, ⁵University of Florida, Department of Medicine; Gainesville, FL, ⁶Banyan 13 Biomarkers, ⁷Gorgas Memorial Institute, Panama City, Panama, ⁸Carson Centre for Research in 14 Environment and Emerging Infectious Diseases, La Peñita, Darién, Panama, ⁹Department of 15 16 Biology, University of Oxford, Oxford, United Kingdom, 17 Corresponding author: Darci R. Smith darci.smith.civ@health.mil Abstract: 18

Background. Blood biomarkers of neurological injury could provide a rapid diagnosis of central nervous system (CNS) injury caused by infections. An FDA-approved assay for mild traumatic brain injury (TBI) measures glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), which signal astrocyte and neuronal injury, respectively. Here, we assessed the applicability of this biomarker assay for determining infection-induced brain injury.

24	Methods. We measured serum levels of GFAP and UCH-L1 retrospectively in serum samples
25	from three study populations: 1) human cases infected with Venezuelan equine encephalitis virus
26	(VEEV) and Madariaga virus (MADV) ($n = 73$), 2) human sepsis patients who were severely ill
27	or diagnosed with encephalitis ($n = 66$), and 3) sepsis cases that were subsequently evaluated for
28	cognitive impairment ($n = 64$).
29	<i>Results</i> . In the virus infection group, we found elevated GFAP for VEEV ($p = 0.014$) and
30	MADV ($p = 0.011$) infections, which correlated with seizures ($p = 0.006$). In the bacterial sepsis
31	group, GFAP was elevated in cases diagnosed with encephalitis ($p = 0.0007$) and correlated with
32	headaches ($p = 0.0002$). In the bacterial sepsis cases with a later cognitive assessment, elevated
33	GFAP ($p = 0.0057$) at study enrollment was associated with cognitive impairment six months
34	later with a positive prognostic capacity of 79% (CI: 66–95%; $p = 0.0068$).
35	Conclusions. GFAP and UCH-L1 levels measured using an FDA-approved assay for TBI may
36	indicate brain injury resulting from viral or bacterial infections and could predict the
37	development of neurological sequelae.
38	Keywords: Six words → Viruses, encephalitis, biomarkers, GFAP, UCH-L1, sepsis

39 Article word count (Background through Discussion): 3,006

40 Background

41	Central nervous system (CNS) infections, which can lead to brain injury via invasion of
42	brain tissue, inflammation, and/or the release of toxins, can be diagnostically challenging (1).
43	Diagnosis requires a combination of clinical assessment, magnetic resonance imaging (MRI)
44	studies and computed tomography (CT) scans, cerebrospinal fluid (CSF) analysis, and
45	identification of the causative pathogen. Neurological injury biomarkers could provide a new
46	approach to the diagnosis of infection-induced CNS injury. The first FDA-approved test for a
47	blood biomarker for acute traumatic brain injury (TBI) detects glial fibrillary acidic protein
48	(GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), which signal astrocyte and
49	neuronal injury, respectively (2). GFAP and UCH-L1 are also used as biomarkers for
50	neurodegenerative diseases in blood or CSF, like multiple sclerosis (3, 4), neuromyelitis optica
51	spectrum disorder (5), Alzheimer's disease (6-8), and less often for CNS infections (9, 10).
52	Venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV),
53	and Madariaga virus (MADV) are important mosquito-borne, single-stranded positive-sense
54	RNA viruses (Togaviridae; Alphavirus) that circulate throughout the Americas and infect the
55	CNS of humans and equids (11). VEEV enzootic/endemic subtype ID infection is prevalent in
56	the eastern province of Darién, Panama, with seroprevalence up to 75% in some villages(11).
57	EEEV was reclassified as two different species in 2010: EEEV in North America and MADV in
58	Latin America (12). MADV was not associated with human outbreaks until 2010 when the first
50	
55	human MADV outbreak was reported in Darién, Panama (13). A force-of-infection model
60	human MADV outbreak was reported in Darién, Panama (13). A force-of-infection model applied to two serosurveys from Darién Province in 2012 and 2017 found endemic alphavirus
60 61	human MADV outbreak was reported in Darién, Panama (13). A force-of-infection model applied to two serosurveys from Darién Province in 2012 and 2017 found endemic alphavirus transmission (14). Alphavirus disease typically presents as a self-limited febrile illness but can be

63 or VEEV exposure (11).

Sepsis, including septicemia, pneumonia, skin infections, and intra-abdominal infections, 64 is a serious and potentially life-threatening consequence of the exaggerated release of cytokines 65 and other inflammatory mediators in response to infection. The inflammatory response leads to 66 cellular injury and organ dysfunction, including the CNS (15). Although bacteria can cause 67 68 meningitis and brain abscesses, CNS injury may result indirectly from cytokine-mediated alterations in the blood-brain barrier (BBB), hypoxia, and microcirculatory abnormalities (13). 69 Sepsis-associated encephalopathy affects about 30% of patients with sepsis and is characterized 70 71 by an altered level of consciousness (16). Sepsis patients who recover often suffer long-term cognitive impairment resulting from BBB disruption, neuroinflammation, neurotransmitter 72 dysfunction, and neuronal loss (17, 18). 73

74 Here, we determined the efficacy of an FDA-approved Brain Trauma Indicator (BTI) biomarker assay, designed for brain injury in mild TBI patients (2), in detecting brain injury 75 caused by infections. The three study populations we evaluated included acute alphavirus cases, 76 sepsis cases, and sepsis cases that were evaluated after recovery for cognitive impairment (Table 77 1). We measured higher levels of GFAP in all cohorts compared to uninfected controls, 78 79 suggesting that GFAP is a good indicator of infection-induced brain injury and may predict neurological sequelae, such as cognitive impairment. This is the first report that supports the use 80 of an FDA-approved blood-based biomarker assay to detect possible neurological injury in viral 81 82 and bacterial infections.

83 Methods

84 Study Populations and Sample Collection Procedures

85 Study Population 1: virus infection group

Sera and metadata were collected from consenting adults and children with parental consent 86 during an acute alphaviral outbreak in 2018-2019 in Aruza, Darién, by the Gorgas Memorial 87 Institute, with negative control serum samples collected from healthy individuals in the region. 88 Sera were deidentified and shipped on dry ice to the Naval Medical Research Command 89 (NMRC). The studies were approved by the Panamanian Ministry of Health (protocol: 2077), the 90 91 Gorgas Institutional Review Board (IRB) (protocol: 335/CBI/ICGES/21), and the University of Florida IRB (protocol: 201500292). 92 Enzyme-linked immunosorbent assays (ELISAs) were used to measure IgM and IgG 93

antibodies to MADV and VEEV and samples were run in duplicate. ELISA antigens were
prepared from the EEEV (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in
August 1989) and VEEV complex strain 78V-3531 (from an infected mouse brain) (11). All
samples were also tested for viruses using virus-specific plaque reduction neutralization tests
(PRNTs). A positive sample was reported as the reciprocal of the highest dilution that reduced
plaque counts by >80% (PRNT₈₀). Reactivity to VEEV (strain TC-83) and MADV (strain GML267113, isolated from a fatal human case in Panama in 2017) was measured (14).

101 Study population 2: bacterial sepsis

Sera from suspected human sepsis cases were collected by NMRC's Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO) program during prospective observational studies in Cambodia and Ghana (19, 20) under IRB-approved protocols (protocols: NMRC.2013.0019 and NMRC.2016.0004-GHA) in compliance with all applicable U.S. Federal regulations governing the protection of human subjects. All subjects, or their legally authorized representatives, provided written informed consent and authorized future use of their specimens and data. Responses were recorded on a standardized case report form and included

demographics, medical history, physical exam findings, and admitting diagnosis. A diagnosis of
a CNS infection was based on the judgment of two physicians. If these two physicians did not
agree on a diagnosis, a third physician reviewed patient records and made the diagnosis. Other
infections were confirmed by culture or polymerases chain reaction (PCR) (supplementary data
and included respiratory tract infection, bacteremia, abscess, cellulitis, gastrointestinal tract
infection, fungemia, oral cavity infection, reproductive tract infection, or cardiovascular infection
(20).

116 Study population 3: bacterial sepsis with cognitive assessment

117 Sera from human sepsis cases were collected by the NMRC ACESO program during 118 prospective observational studies in Ghana as described above for study population 2. Sera were 119 collected at enrollment (day 0; n = 64) or day 28 after enrollment (day 28; n = 38). Impairment 120 was assessed using the Montreal Cognitive Assessment Basic (MoCA-B) (21) for individuals at 121 enrollment (n = 64), upon discharge (n = 64), day 28 (n = 38), and months 6 (n = 32) and 12 (n =122 20) after discharge, as available.

123 GFAP and UCH-L1 Assays

124 Sera was evaluated with the Banyan BTI assay according to the manufacturer's guidelines.

125 Antibodies were vortexed, diluted in antibody diluent, and kit standards prepared following a

serial dilution (UCH-L1: 2,560 pg/mL to 80 pg/mL; GFAP 320 pg/mL to 10 pg/mL). Serum was

added to plates (UCH-L1: 25 μ L; GFAP: 50 μ L) in duplicate and incubated for 60 minutes at 37

- 128 °C with shaking at 500 rpm. Plates were washed, detection antibody added and allowed to
- incubate for 60 minutes at 37 °C while shaking at 500 rpm. Plates were washed and 150 μ L of
- 130 substrate added per well prior to reading optical density at 225 nm. If the concentration exceeded
- 131 the upper limit of quantitation, serum was diluted and re-run. Samples that were below the lower

132	limit of quantitation (LLOQ) were included at half the minimum LLOQ for statistical analyses.
133	The cutoff for positivity for mild TBI in the BTI assay is 327 pg/mL UCH-L1 and 22 pg/mL

134 GFAP.

135 Statistical Analyses

136 Statistical analyses were performed using SPSS (Version 19.0. Armonk, NY: IBM Corp) or

137 GraphPad v9 and included the Mann-Whitney U test following normality testing, the

138 Jonckheere–Terpstra (JT) test, and area under the curve plots. A chi-square test was used to

139 determine statistical significance for age and sex differences. The relevant tests are indicated in

140 figure legends.

141

142 **Results**

143 Study Population 1: Virus Infection

For population 1, serum samples were collected from 33 cases of acute alphavirus infection in 144 eastern Panama. Subjects with confirmed infections tested positive for VEEV, MADV, or both 145 by IgM ELISA and PRNT (Supplemental Table 1), whereas subjects with likely infection tested 146 positive for either IgM ELISA or PRNT. Symptoms consistent with alphavirus illness included 147 fever, chills, headaches, and, less commonly, myalgia, arthralgia, nausea, vomiting, and seizures 148 (Figure 1A, Table 2). Patients infected with MADV had a higher incidence of seizures (37.5%) 149 compared to those infected with VEEV ID (5.0%), and the only fatality occurred in an individual 150 with MADV. Serum levels of GFAP and UCH-L1 were determined with the BTI assay for 151 uninfected controls and the alphavirus-positive individuals. Mean UCH-L1 levels were 152 153 significantly lower in cases of VEEV but not in cases of MADV, whereas the mean GFAP levels were significantly higher for subjects with either alphavirus (Figure 1B). However, UCH-L1 was 154

155	elevated in the fatal case and in two out of the four cases with seizures. The highest levels of
156	GFAP were observed in three of the four cases with seizures and the fatal case. When grouped
157	by time since onset of fever (early 0–7 days, mid 8–14 days, or late >15 days), UCH-LI
158	decreased ($p = 0.00031$) during the mid-timeframe and was statistically unchanged either early or
159	late (Figure 1C). However, GFAP was elevated at the early $(p = 0.013)$ and mid $(p = 0.0059)$
160	timeframes but not late ($p = 0.092$) (Figure 1C), which may be due to the small sample size at
161	this time point. For symptoms, seizures were significantly associated with higher levels of GFAP
162	(p = 0.006) (Table 2). Interestingly, GFAP levels were higher in those without inflammatory
163	response symptoms, including fever, chills, and myalgia, and this increase was statistically
164	significant for chills ($p = 0.023$). There were no significant associations between levels of UCH-
165	L1 and symptoms. A Wilcoxon rank-sum analysis indicated that the relationship between GFAP
166	and acute alphavirus infection, i.e., infection with both VEEV and MADV, acute MADV
167	infection, or acute VEEV infection was strengthened, while the relationship between UCH-L1
168	and any infection remained unchanged (Supplemental Table 2). These results suggest that GFAP
169	may be a promising biomarker of acute alphavirus disease and may indicate disease severity.

170

171 Study Population 2: Bacterial Sepsis

We analyzed patient samples from sepsis studies completed in Cambodia (20) and Ghana (19) to measure changes in UCH-L1 or GFAP as a result of bacterial infection. This study population was comprised of 53 severely ill, hospitalized patients who presented with at least two systemic inflammatory response syndrome criteria and a suspected infection. These included a sepsis cohort with symptoms consistent with CNS disease (n = 21) and individuals without symptoms of CNS disease but positive for infection (n = 32). A control group (n = 13) comprised healthy

individuals from the same region. A diagnosis of a CNS infection was determined after a review 178 by two physicians of the patient's medical history, which included evaluation for nerve palsies, 179 paralysis, reflex response abnormalities, and assessment by the Glasgow coma scale. The 180 severely ill patients presented with fever, headache, abdominal pain, nausea, and diarrhea (Figure 181 2A). This cohort reported more myalgia than the alphavirus cohort; however, there was no 182 183 difference in myalgia between CNS and other infections. Serum levels of GFAP and UCH-L1 were determined with the BTI assay for control samples, the severely ill individuals with no 184 signs of a CNS infection, and those diagnosed with a CNS infection. We found no significant 185 186 differences in UCH-L1 levels; however, GFAP levels were significantly higher in individuals with CNS infections and elevated, although not significantly, in patients with non-CNS 187 infections (Figure 2B). Also, patients with fatal vs. non-fatal cases had similar levels of UCH-L1 188 and GFAP. Among symptoms, headache was positively associated with GFAP (p = 0.0002) but 189 negatively associated with UCH-L1 (p < 0.0001) (Table 3). These results are similar to those for 190 our viral infection study population (group 1) and indicate that elevated levels of GFAP may be a 191 potential biomarker to indicate CNS infection. 192

193 Study Population 3: Bacterial Sepsis with Cognitive Assessment

194 Finally, we determined whether the levels of these biomarkers measured at study enrollment

195 would predict cognitive impairment after sepsis based on MoCA-B scores, which were measured

- 196 during study enrollment and on subsequent visits up to a year later. MoCA-B scoring
- 197 differentiates among cognitive syndromes by assessing memory, executive function, attention,
- language, visuospatial parameters, and orientation (21). A normal score is \geq 26, whereas
- impairment falls into mild (18–25), moderate (10–17), and severe (< 10) categories. Previous
- sepsis studies completed in Ghana (19) provided serum samples collected prospectively from

201 hospitalized cases of sepsis at study enrollment (day 0) and day 28 after enrollment. MoCA-B scores were determined for individuals at study enrollment, upon discharge, on day 28, and 6 and 202 12 months after discharge, when feasible. Levels of UCH-L1 and GFAP were measured in 203 individuals at study enrollment (day 0) and day 28 after enrollment. Mean UCH-L1 levels were 204 unchanged, whereas the mean GFAP levels were significantly higher at both time points (Figure 205 206 3A). We then evaluated the levels of GFAP and UCH-L1 at study enrollment (day 0) stratified by the average MoCA score after discharge and up to 12 months later. Levels of UCH-L1 207 trended higher in cases with severe cognitive impairment and persisted up to 12 months after 208 209 symptom onset; however, they did not reach statistical significance (Figure 3B). Levels of GFAP in serum at study enrollment increased with increasing levels of cognitive impairment vs. 210 controls up to twelve months after study enrollment (Figure 3B). The percentage of individuals 211 212 who developed cognitive impairment after discharge from the hospital was compared to the results of the BTI assay at study enrollment (Table 4). Individuals with a higher level of 213 cognitive impairment after discharge were more likely to have had a positive BTI assay at study 214 enrollment. Thus, the Banyan BTI assay may predict the development of reduced cognitive 215 function after infection. Supporting these associations, trends for UCH-L1 (p = 0.00363) and 216 GFAP ($p = 1.849 \times 10^{-8}$) were significant by the JT test for ranked categories. Thus, serum 217 GFAP levels at study enrollment predicted cognitive impairment as measured by MoCA-B 218 219 scores at six months. The six-month time point was chosen for comparison because the sample 220 size was split equally between patients with normal (≥ 26) or impaired (≤ 26) MoCA-B scores. Not only was cognitive impairment associated with higher levels of GFAP at enrollment (p =221 0.0057), but this metric should identify 79% (CI: 66-95%; p=0.0068) of cases correctly based on 222 223 time-dependent receiver operating characteristic (ROC) curves (Figure 3C and Figure 3D).

Therefore, GFAP levels may serve as an effective biomarker for predicting the development ofcognitive impairment in individuals with severe infectious diseases.

226 **Discussion**

We evaluated two brain biomarkers using an FDA-approved BTI assay developed 227 originally for acute TBI, in which elevation of either or both biomarkers are considered 228 229 indicative of brain injury (2). GFAP is an intermediate filament protein expressed almost exclusively in astrocytes, where it is induced by neural injury and released upon disintegration of 230 the astrocyte cytoskeleton (22). UCH-L1 is expressed only in neurons where it is involved in the 231 ubiquitination of proteins intended for degradation by the proteasomal pathway and plays an 232 important role in the removal of oxidized or misfolded proteins in both normal and pathological 233 234 conditions (8). Analyzing both GFAP and UCH-L1 may reflect distinct causes of brain injury. In severe TBI, focal mass lesions cause an increase in GFAP, whereas diffuse brain injuries cause 235 an increase in UCH-L1 (23, 24). Here, we found a significant increase in GFAP, but not UCH-236 L1, in the alphavirus and sepsis cohorts, suggesting that GFAP is a shared biomarker for brain 237 injury and infectious diseases of the CNS. 238

Previous work on biomarkers, including GFAP, analyzed only the CSF, not serum from 239 240 viral encephalitis cases, and none used an FDA-approved assay (25-30). Early identification of sepsis-associated encephalopathy, one of the most serious clinical manifestations of sepsis (31), 241 242 would provide a more accurate diagnosis and prognosis, which now relies on nonspecific clinical manifestations and imaging features, often followed by lumbar punctures and 243 electroencephalograms. Several biomarkers have been proposed for the rapid detection of sepsis-244 245 related brain injury (32), including serum GFAP and UCH-L1, which correlate with the occurrence, severity, and prognosis of sepsis-associated encephalopathy (33, 34). We found 246

higher levels of GFAP in acute CNS-involved sepsis, and these higher levels of serum GFAP at
the time of hospitalization correlated with cognitive decline up to twelve months after symptom
onset in our group 3 cohort. We also observed elevated UCH-L1, similar to the previous study
(33), but it was not statistically significant, which may be due to the sample size or time of
sampling. Therefore, GFAP and possibly UCH-L1 may serve as biomarkers for sepsis-related
brain injury and should be further evaluated.

253 Lesions in the brain of fatal human VEEV cases appear to result from injury due to virus replication and clearance of infected cells by the immune system (35). Although neurons are the 254 255 primary targets of encephalitic alphaviruses and viral cytopathology is important in CNS dysfunction, fatal encephalitis is likely mediated by the immune response to infection rather than 256 257 direct virus replication (36). For individuals infected by the encephalitic alphaviruses, mean 258 levels of GFAP and the incidence of seizures were significantly higher than controls, whereas the mean UCH-L1 levels were reduced significantly in VEEV but not MADV. The latter results 259 were unexpected because neurons are the major target cells of the encephalitic alphaviruses, but 260 these results may be due to the time of sampling. In cell culture and animal models, encephalitic 261 alphaviruses also infect astrocytes (37-39), which are immuno-activated in infected animals (36). 262 263 Our GFAP results likely indicate that astrocytes were injured by virus infection or the immune response. 264

Our results suggests that GFAP levels may serve as an effective biomarker for predicting the development of cognitive impairment in individuals with severe infectious diseases. Neurological sequelae after recovery from alphavirus infection occurs frequently and includes seizures, paralysis, intellectual disability, behavioral changes, photophobia, coma, or visual disturbances (11, 40). GFAP may predict the development of neurologic sequelae after

alphavirus infection, similar to our results with the bacterial sepsis cohort, and is a focus of ourfuture studies.

272	In conclusion, CNS infections have high rates of morbidity and mortality and blood-
273	based diagnostic assays for brain injury could aid clinicians when deciding whether imaging is
274	needed and to initiate treatment. Our data support the use of the BTI assay to identify brain
275	injury caused by CNS infection that could lead to neurological sequelae. Further research is
276	needed to identify the relevant timeframes, examine additional cohorts, and conduct clinical
277	trials to determine the impact of this assay on patient outcomes. Our study lays the foundation
278	for these efforts.

279 Tables

Group	Subgroup	Serum (N)	Country	Reference
1—Virus Infection	Acute MADV	8	Panama	N/A
	Acute VEEV	22	-	
	Both (MADV/VEEV)	3	-	
	Controls ¹	40		
2—Bacterial Infection (Sepsis)	CNS Infection	21	Ghana n=10, Cambodia n=11	20, 21
	Other Infection	32	Ghana n=14, Cambodia n=18	
	Controls ²	13	Ghana	21
3—Bacterial Infection (Sepsis with	Study Enrollment (day 0)	64	Ghana	21
Cognitive Assessment)	28 Days Post Enrollment	38		

Table 1. Study populations for neurological injury biomarker assessment

	Controls ²	13		
--	-----------------------	----	--	--

- ¹Group 1 controls are samples from the region that were negative for VEEV/MADV by all assays.
- 2 Group 2 and 3 controls were healthy individuals from the region.
- 283

Table 2. Associations between symptoms and biomarkers for group 1 virus infection study

population. Clinical symptoms reported in 30 cases for which sex was reported. Statistical

significance was determined by a chi-square test.

	N	GFAP pg/ml (95% CI)	p-value	UCH-L1 pg/ml (95% CI)	p-value
Sex					
Male	22	70.4 (-20.4, 161.2)	0.482	281.4 (143.2, 419.6)	0.159
Female	8	38.0 (13.8, 62.2)		369.3 (159.0, 579.7)	
Age (mean)					
0-10	8	157.6 (-121.1, 436.2)	0.881	494.8 (109.0, 880.6)	0.306
11-20	8	25.4 (2.8, 48.0)		260.7 (103.5, 418.0)	
21-30	6	18.8 (6.7, 30.9)		188.3 (134.6, 242.0)	
31-40	5	28.4 (-22.6, 79.3)		160.7 (76.5, 244.8)	
>41	3	44.7 (-19.8, 109.3)		389.5 (-483.7, 1262.8)	
Fever		-		•	-
Yes	23	33.4 (20.9, 46.0)	0.391	295.3 (173.0, 417.6)	0.902
No	7	154.8 (-182.0, 491.5)		336.3 (7.2, 665.4)	
Chills					
Yes	13	20.4 (7.0, 33.8)	0.023	222.5 (128.1, 316.9)	0.277
No	17	93.4 (-25.0, 211.7)		367.9 (182.5, 553.2)	
Headache		-	·	-	-
Yes	16	22.9 (11.7, 34.1)	0.135	243.5 (161.8, 325.2)	0.868
No	14	106.2 (-40.1, 252.5)		375.0 (145.9, 604.1)	
Arthralgia					
Yes	9	19.8 (4.2, 35.5)	0.08	232.1 (69.3, 394.9)	0.205
No	21	79.7 (-15.1, 174.5)		336.0 (188.5, 483.6)	
Myalgia		-	·	-	-
Yes	5	16.4 (6.7, 26.1)	0.303	195.1 (125.4, 264.7)	0.636
No	25	70.8 (-8.24, 149.9)		326.8 (195.1, 458.5)	
Nausea		-		-	-
Yes	7	38.0 (8.9, 67.1)	0.508	328.7 (128.7, 528.7)	0.447
No	23	69.0 (-17.6, 155.6)		297.6 (159.5, 435.7)	
Vomiting		-		-	-
Yes	10	40.2 (16.8, 63.6)	0.482	382.5 (118.3, 646.7)	0.218
No	20	72.5 (-28.0, 173.0)		266.0 (147.9, 384.2)	

Abdominal pain			-	<u>.</u>	-	-
	Yes	3	32.7 (-52.2, 117.6)	0.863	357.1 (-569.6, 1283.7)	0.809
	No	27	65.0 (-8.12, 138.1)		299.1 (182.9, 415.2)	
Diarrhea			-			-
	Yes	2	25.1 (-204.9, 255.1)	0.678	224.6 (-534.6, 983.7)	0.868
	No	28	64.4 (-6.01, 134.7)		310.6 (192.4, 428.8)	
Lower back pain			-			-
	Yes	1	17.1	0.862	229.8	0.773
	No	29	623.3 (-4.6, 131.1)		307.4 (193.3, 421.6)	
Seizures			-			-
	Yes	4	302.6 (-417.4, 1022.7)	0.006	665.5 (-329.0, 1659.9)	0.428
	No	26	24.7 (16.3, 33.1)		249.4 (179.1, 319.6)	

- **Table 3.** Associations between symptoms and biomarkers in group 2 bacterial infection (sepsis).
- 289 Statistical significance was determined by a chi-square test.

	N	GFAP pg/ml (95% CI)	p-value	UCH-L1 pg/ml (95% CI)	P-value
Sex			0.1490		0.1793
Male	49	27.1 (15.0, 39.2)		807.1 (197.7, 1416)	
Female	4	49.3 (19.3, 79.4)		281.1 (173.4, 388.7)	
Age (mean)			0.424		0.9144
11-20	3	6.767 (-0.199, 13.7)		529.1 (-1298, 2356)	
21-30	5	82.84 (-10.55, 176.2)		2818 (-4244-9880)	
31-40	10	35.76 (8.028, 63.49)		416 (70.84, 761.2)	
>41	35	44.68 (25.41, 63.95)		535.1 (233.5, 836.7)	
Fever	-		0 8704		0.9376
Yes	36	36 02 (25 20 46 84)	0.0701	352 0 (247 3 456 7)	0.7570
No	13	63 46 (6 191 120 7)		883.0 (37.25, 1729)	
110	15				
Headache			0.0002		< 0.0001
Yes	44	428.7 (205.7, 651.8)		43.41 (26.21, 60.61)	
No	5	42.34 (-28.95,113.6)		1058 (-277.8,2393)	
Arthralgia			0.5708		0.9455
Yes	6	63.83 (-7.523, 135.2)		327.0 (106.2, 547.8)	
No	47	41.97 (26.37, 135.2)		778.8 (195.3, 1362)	
Myalgia			0.1299		0.9811
Yes	2	75.70 (-236.9, 38.3)		316.0 (188.7, 2012)	
No	51	43.22 (27.7, 58.75)		743.8 (206.3, 1281)	
Abdominal pain			0.0793	•	0.3775
Yes	23	48.89 (31.96, 65.82)		944.3 (-199.5, 2088)	
No	30	41.04 (16.92, 65.17)		561.6 (200.1, 923.1)	

Diarrhea		-	-	0.3224		0.2149
	Yes	21	36.46 (19.82,53.10)	3	76.9 (182.6, 571.3)	
	No	32	49.69 (26.65, 72.73)	9	57.8 (101.0, 1815)	

291 Table 4. Cognitive impairment on follow up in group 3 bacterial infection (sepsis with cognitive

assessment).

MoCA category	Cognitive impairment after discharge	BTI positive at enrollment
	percentage (n)	percentage (n)
Normal (≥26)	8.2% (5)	20% (1)
Mild (25-18)	49.2% (30)	46.7 % (14)
Moderate (17-10)	26.2% (16)	56.3% (9)
Severe (<10)	16.4% (9)	100% (9)

305 Figures









UCH-L1





307	Figure 1. Neurotropic alphavirus exposure cases in Panama from the group 1 virus infection
308	study population. A) $(n = 31)$ were grouped based on antibody reactivity to MADV $(n = 7)$,
309	VEEV ($n = 21$), and both ($n = 3$). B) UCH-L1 and GFAP levels (pg/mL) in patient serum ($n = 1$)
310	33), where each point represents a single patient: MADV ($n = 8$), VEEV ($n = 22$), both ($n = 3$)
311	and negative $(n = 40)$. Blue points represent patients with seizures $(n = 4)$, and red indicates
312	mortality ($n = 1$). Comparison of analyte levels in patients grouped by positive or negative for
313	any virus and days of clinical evolution: early (0–7), mid (8–14), late (>15) for C) UCH-L1 and
314	GFAP (pg/mL). Blue points represent patients with seizures ($n = 4$), and red indicates mortality
315	(n = 1). Statistical significance is based on Mann-Whitney U test vs. negative controls for both

316 viruses.



Figure 2. Severe, hospitalized acute febrile illness cases in Ghana and Cambodia with or without
CNS involvement in the group 2 bacterial sepsis cohort. A) Patient-reported symptoms were
grouped based on the clinical designation of CNS infection determined by two physicians. B)
UCH-L1 and GFAP levels (pg/mL) grouped by CNS, other, or controls. Statistical significance is
based on comparison biomarker values at corresponding time points using Mann-Whitney U test
vs. healthy controls.



326	Figure 3. Longitudinal study of group 3 severe bacterial sepsis with cognitive assessment. A)
327	UCH-L1 and GFAP levels (pg/mL) in patient sera from Ghana and Cambodia grouped by study
328	enrollment (day 0) or day 28 post enrollment compared to controls. B) UCH-L1 and GFAP
329	(pg/mL) levels in sera from patients grouped by the average MoCA severity score at discharge
330	and up to six months later. Statistical significance is based on values at corresponding time
331	points using Mann-Whitney U test vs. controls. No MoCA surveys were obtained from controls.
332	C) Comparison of UCH-L1 and GFAP between patients with normal (\geq 26) or impaired (<26)
333	MoCA severity scores at six months post enrollment. D) AUC analysis of the predictive value of
334	GFAP at study enrollment to impaired cognitive function six months later.
335	Authors' contributions
336	ML Bartlett, DR Smith, and A Vittor had full access to the study data and take full responsibility
337	for the integrity and accuracy of this analysis. Concept and design: ML Bartlett, DR Smith, A
338	Vittor, R Hayes; Data acquisition, analysis, and interpretation: ML Bartlett, DR Smith, A Vittor,
339	R Hayes, JP Carrera, LF Rivera, C Lezcano-Coba, J Galue, KL Schully, M Gregory, J
340	Brandsma, JG Chenoweth, DV Clark; Laboratory analysis: DR Smith, J Linwood, H Goux, JP
341	Carrera, C Lezcano-Coba and J Galue; Drafting of the manuscript: ML Bartlett, DR Smith; KL
342	Schully, JG Chenoweth, R Hayes, JP Carrera; Statistical analysis: ML Bartlett, A Vittor, J
343	
	Brandsma.

344 Funding

The funder was not involved in the study design, analysis, and interpretation of data, writing ofthe report, or the decision to submit the study results for publication.

347 Declaration Competing of Interest

348 The authors of this manuscript have no conflicts of interest to disclose.

349 Acknowledgments

- 350 This study was supported by the Defense Threat Reduction Agency under project number
- 351 CB10937 to DRS and grant number FID-2021-96 SENACYT to JPC. The views expressed in
- this work reflect the results of research conducted by the authors and do not necessarily reflect
- the official policy or position of the Department of Defense, the Navy, or the United States
- 354 Government. Several of the authors are U.S. Government employees. This work was prepared as
- part of their official duties. Title 17, U.S.C., § 105 provides that copyright protection under this
- title is not available for any work of the U.S. Government. Title 17 U.S.C., § 101 defines a U.S.
- 357 Government work as work prepared by a military Service member or employee of the U.S.
- 358 Government as part of that person's official duties.

359 **References**

- McGill F GM, Bonnett LJ, Geretti AM, Michael BD, Beeching NJ, McKee D, Scarlett P, Hart IJ, Mutton KJ, Jung A, Adan G, Gummery A, Sulaiman WAW, Ennis K, Martin AP, Haycox A, Miller A, Solomon T; UK 2018. Meningitis Study Investigators. Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort study. Lancet Infect Dis doi: doi: 10.1016/S1473-3099(18)30245-7.
- Bazarian JJ, Biberthaler P, Welch RD, Lewis LM, Barzo P, Bogner-Flatz V, Gunnar Brolinson P,
 Buki A, Chen JY, Christenson RH, Hack D, Huff JS, Johar S, Jordan JD, Leidel BA, Lindner T,
 Ludington E, Okonkwo DO, Ornato J, Peacock WF, Schmidt K, Tyndall JA, Vossough A, Jagoda
 AS. 2018. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT
 (ALERT-TBI): a multicentre observational study. Lancet Neurol 17:782-789.
- Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle
 J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. 2022. Blood GFAP as an emerging
 biomarker in brain and spinal cord disorders. Nat Rev Neurol 18:158-172.
- Biernacki T, Kokas Z, Sandi D, Füvesi J, Fricska-Nagy Z, Faragó P, Kincses TZ, Klivényi P, Bencsik K, Vécsei L. 2022. Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations. International journal of molecular sciences 23:3383.
- 5. Kim H, Lee E-J, Lim Y-M, Kim K-K. 2022. Glial Fibrillary Acidic Protein in Blood as a Disease
 Biomarker of Neuromyelitis Optica Spectrum Disorders. Frontiers in Neurology 13.
- O'Connor A, Abel E, Benedet AL, Poole T, Ashton N, Weston PSJ, Heslegrave AJ, Ryan N, Barker
 S, Polke JM, Blennow K, Zetterberg H, Fox NC. 2023. Plasma GFAP in presymptomatic and
 symptomatic familial Alzheimer's disease: a longitudinal cohort study. J Neurol Neurosurg
 Psychiatry 94:90-92.
- Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, Verberk IMW, Dave P,
 Taddei K, Sohrabi HR, Zetterberg H, Blennow K, Teunissen CE, Vanderstichele HM, Martins RN.

Alzheimer's disease. Translational Psychiatry 11:27.

2021. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of

385

386

Gong B, Leznik E. 2007. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative 387 8. 388 disorders. Drug News Perspect 20:365-70. Cooper J. Stukas S, Hoiland RL, Fergusson NA, Thiara S, Foster D, Mitra A, Stoessl JA, Panenka 9. 389 WJ, Sekhon MS, Wellington CL. 2020. Quantification of Neurological Blood-Based Biomarkers 390 391 in Critically Ill Patients With Coronavirus Disease 2019. Crit Care Explor 2:e0238. 392 10. de Menezes EGM, Liu JS, Bowler SA, Giron LB, D'Antoni ML, Shikuma CM, Abdel-Mohsen M, 393 Ndhlovu LC, Norris PJ. 2022. Circulating brain-derived extracellular vesicles expressing 394 neuroinflammatory markers are associated with HIV-related neurocognitive impairment. Front Immunol 13:1033712. 395 396 11. Carrera JP, Pitti Y, Molares-Martinez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I, Galue J, 397 Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly CA, Vittor AY. 398 2020. Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral 399 Infections: A Follow-up Study 5 Years After an Outbreak in Panama. Open Forum Infect Dis 400 7:ofaa359. Arrigo NC, Adams AP, Weaver SC. 2010. Evolutionary patterns of eastern equine encephalitis 401 12. 402 virus in North versus South America suggest ecological differences and taxonomic revision. J Virol 403 84:1014-25. 404 13. Carrera JP, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I, Castaño E, Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG, Travassos da Rosa AP, 405 406 Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. 2013. Eastern equine encephalitis in 407 Latin America. N Engl J Med 369:732-44. Carrera JP, Cucunubá ZM, Neira K, Lambert B, Pittí Y, Liscano J, Garzón JL, Beltran D, Collado-408 14. 409 Mariscal L, Saenz L, Sosa N, Rodriguez-Guzman LD, González P, Lescano AG, Perevra-Elías R, 410 Valderrama A, Weaver SC, Vittor AY, Armién B, Pascale JM, Donnelly CA. 2020. Endemic and Epidemic Human Alphavirus Infections in Eastern Panama: An Analysis of Population-Based 411 412 Cross-Sectional Surveys. Am J Trop Med Hyg 103:2429-2437. 413 15. Yan X, Yang K, Xiao Q, Hou R, Pan X, Zhu X. 2022. Central role of microglia in sepsis-associated encephalopathy: From mechanism to therapy. Frontiers in Immunology 13. 414 415 16. Mazeraud A, Righy C, Bouchereau E, Benghanem S, Bozza FA, Sharshar T. 2020. Septic-Associated Encephalopathy: a Comprehensive Review. Neurotherapeutics 17:392-403. 416 Li Y, Ji M, Yang J. 2022. Current Understanding of Long-Term Cognitive Impairment After Sepsis. 417 17. Front Immunol 13:855006. 418 Iwashyna TJ, Ely EW, Smith DM, Langa KM. 2010. Long-term cognitive impairment and 419 18. 420 functional disability among survivors of severe sepsis. Jama 304:1787-94. 421 19. Blair PW, Mehta R, Oppong CK, Tin S, Ko E, Tsalik EL, Chenoweth J, Rozo M, Adams N, Beckett 422 C, Woods CW, Striegel DA, Salvador MG, Brandsma J, McKean L, Mahle RE, Hulsey WR, 423 Krishnan S, Prouty M, Letizia A, Fox A, Faix D, Lawler JV, Duplessis C, Gregory MG, Vantha T, 424 Owusu-Ofori AK, Ansong D, Oduro G, Schully KL, Clark DV. 2023. Screening tools for predicting mortality of adults with suspected sepsis: an international sepsis cohort validation study. BMJ Open 425 13:e067840. 426 427 20. Rozo M, Schully KL, Philipson C, Fitkariwala A, Nhim D, Som T, Sieng D, Huot B, Dul S, Gregory MJ, Heang V, Vaughn A, Vantha T, Prouty AM, Chao CC, Zhang Z, Belinskaya T, Voegtly LJ, 428 429 Cer RZ, Bishop-Lilly KA, Duplessis C, Lawler JV, Clark DV. 2020. An Observational Study of Sepsis in Takeo Province Cambodia: An in-depth examination of pathogens causing severe 430 431 infections. PLoS Negl Trop Dis 14:e0008381. Julayanont P, Tangwongchai S, Hemrungrojn S, Tunvirachaisakul C, Phanthumchinda K, 432 21. Hongsawat J, Suwichanarakul P, Thanasirorat S, Nasreddine ZS. 2015. The Montreal Cognitive 433 434 Assessment-Basic: A Screening Tool for Mild Cognitive Impairment in Illiterate and Low-435 Educated Elderly Adults. J Am Geriatr Soc 63:2550-2554.

- 436 22. Eng LF, Ghirnikar RS, Lee YL. 2000. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res 25:1439-51.
- 438 23. Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F,
 439 Wang KK, Hayes RL. 2012. Glial neuronal ratio: a novel index for differentiating injury type in
 440 patients with severe traumatic brain injury. J Neurotrauma 29:1096-104.
- 441 24. Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL. 2011.
 442 Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15:R156.
- DeKosky ST, Kochanek PM, Valadka AB, Clark RSB, Chou SH, Au AK, Horvat C, Jha RM,
 Mannix R, Wisniewski SR, Wintermark M, Rowell SE, Welch RD, Lewis L, House S, Tanzi RE,
 Smith DR, Vittor AY, Denslow ND, Davis MD, Glushakova OY, Hayes RL. 2021. Blood
 Biomarkers for Detection of Brain Injury in COVID-19 Patients. J Neurotrauma 38:1-43.
- 448 26. Teunissen CE, Rohlwink U, Pajkrt D, Naudé PJW. 2022. Biomarkers of Tuberculous Meningitis and Pediatric Human Immunodeficiency Virus on the African Continent. Front Neurol 13:793080.
- 450 27. Rohlwink UK, Figaji AA. 2014. Biomarkers of Brain Injury in Cerebral Infections. Clinical 451 Chemistry 60:823-834.
- 452 28. Grahn A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M. 2013. Cerebrospinal fluid
 453 biomarkers in patients with varicella-zoster virus CNS infections. J Neurol 260:1813-21.
- Abdelhak A, Foschi M, Abu-Rumeileh S, Yue JK, D'Anna L, Huss A, Oeckl P, Ludolph AC, Kuhle
 J, Petzold A, Manley GT, Green AJ, Otto M, Tumani H. 2022. Blood GFAP as an emerging
 biomarker in brain and spinal cord disorders. Nature Reviews Neurology 18:158-172.
- 457 30. Constant O, Barthelemy J, Nagy A, Salinas S, Simonin Y. 2022. West Nile Virus Neuroinfection
 458 in Humans: Peripheral Biomarkers of Neuroinflammation and Neuronal Damage. Viruses 14.
- 31. Zhang LN, Wang XT, Ai YH, Guo QL, Huang L, Liu ZY, Yao B. 2012. Epidemiological features and risk factors of sepsis-associated encephalopathy in intensive care unit patients: 2008-2011. Chin Med J (Engl) 125:828-31.
- 462 32. Tang C, Zhou, W., Chen, X. et al. . 2023. Research Progress of Biomarkers of Sepsis-Associated
 463 Encephalopathy. Intensive Care Research 3:69-76.
- Wu L, Ai ML, Feng Q, Deng S, Liu ZY, Zhang LN, Ai YH. 2019. Serum glial fibrillary acidic
 protein and ubiquitin C-terminal hydrolase-L1 for diagnosis of sepsis-associated encephalopathy
 and outcome prognostication. J Crit Care 52:172-179.
- 467 34. Yan S, Gao M, Chen H, Jin X, Yang M. 2019. [Expression level of glial fibrillary acidic protein and its clinical significance in patients with sepsensis-associated encephalopathy]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 44:1137-1142.
- de la Monte S, Castro F, Bonilla NJ, Gaskin de Urdaneta A, Hutchins GM. 1985. The systemic
 pathology of Venezuelan equine encephalitis virus infection in humans. Am J Trop Med Hyg
 34:194-202.
- 473 36. Steele KE, Twenhafel NA. 2010. REVIEW PAPER: pathology of animal models of alphavirus encephalitis. Vet Pathol 47:790-805.
- 475 37. Garen PD, Tsai TF, Powers JM. 1999. Human eastern equine encephalitis: immunohistochemistry
 476 and ultrastructure. Mod Pathol 12:646-52.
- Peng BH, Borisevich V, Popov VL, Zacks MA, Estes DM, Campbell GA, Paessler S. 2013.
 Production of IL-8, IL-17, IFN-gamma and IP-10 in human astrocytes correlates with alphavirus attenuation. Vet Microbiol 163:223-34.
- 39. Schoneboom BA, Fultz MJ, Miller TH, McKinney LC, Grieder FB. 1999. Astrocytes as targets for
 Venezuelan equine encephalitis virus infection. J Neurovirol 5:342-54.
- 482 40. Ronca SE, Dineley KT, Paessler S. 2016. Neurological Sequelae Resulting from Encephalitic
 483 Alphavirus Infection. Front Microbiol 7:959.